榎木 裕紀 (エノキ ユウキ)

Enoki, Yuki

写真a

所属(所属キャンパス)

薬学部 薬学科 薬効解析学講座 (芝共立)

職名

助教

 
 

著書 【 表示 / 非表示

  • 調剤と情報-高齢者の低栄養と薬-

    榎木 裕紀松元 一明, じほう, 2018年10月

    担当範囲: 高齢者が低栄養になるとどうなる?-体内動態の変化と服薬上のリスク-

  • 新薬展望2018

    松元 一明榎木 裕紀, 医薬ジャーナル, 2018年02月

    担当範囲: 抗菌薬

論文 【 表示 / 非表示

  • Experimental verification of factors influencing calcium salt formation based on a survey of the development of ceftriaxone-induced gallstone-related disorder

    Ito R., Yoshida A., Taguchi K., Enoki Y., Yokoyama Y., Matsumoto K.

    Journal of Infection and Chemotherapy (Journal of Infection and Chemotherapy)  25 ( 12 ) 972 - 978 2019年12月

    ISSN  1341321X

     概要を見る

    © 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases Ceftriaxone (CTRX) forms salts with calcium (Ca) in the gall bladder and bile duct, and induces the formation of gallstones. In this study, factors of CTRX-induced gallstone formation were extracted from the results of a retrospective survey using the Japanese Adverse Drug Event Report (JADER), and the causal relationship between the factors and gallstone formation was investigated. From JADER, 136 patients who developed ‘gallstone-related disorder’ with CTRX as a suspected drug were extracted. The incidence of gallstone-induced adverse effects was high in patients treated with CTRX at a dose exceeding the normal daily dose and in children younger than 10 years old, suggesting that CTRX at a high level is a factor for gallstone formation. Thus, after mixing CTRX and Ca2+ at different concentrations under different pH condition, the number of particles in the solutions was measured using a Coulter counter. As a result, the number of minute particles significantly increased at all pH values when Ca2+ and CTRX were mixed at a concentration of 10 mEq/L or higher and 1.5 g/L or higher, respectively. At pH 6.5 or 7.0, visible crystals were detected when 25 mEq/L of Ca2+ and 2.0 g/L of CTRX were mixed. Based on these findings, attention should be sufficiently paid to the development of ‘gallstone-related disorder’ in pediatric patients and in patients treated with CTRX at a dose exceeding the normal dose. Furthermore, gallstone formation and growth may be promoted when CTRX and Ca2+ coexist at high concentrations under low pH conditions.

  • Evaluation for optimal dosing of vancomycin in patients with different physical types

    Hashimoto M., Iketani O., Ichinose N., Enoki Y., Taguchi K., Uno S., Uwamino Y., Hasegawa N., Matsumoto K.

    Journal of Infection and Chemotherapy (Journal of Infection and Chemotherapy)  25 ( 9 ) 735 - 737 2019年09月

    ISSN  1341321X

     概要を見る

    © 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases The sufficient dose to obtain an optimal trough concentration of vancomycin (VCM) in patients with non-standard physical types remains controversial. In this study, we examined the relationship between the dose and physical type in patients in whom an optimal trough concentration was obtained among VCM-treated patients. We retrospectively investigated the dose of VCM and physical type in patients treated with VCM between January 2012 and January 2017 at two medical institutions (n = 272). The physical type was classified using the body mass index (BMI). Patients with a BMI of <18.5 kg/m2 were assigned to the lean group, those with a BMI of 18.5–24.9 kg/m2 were assigned to the standard group, and those with a BMI of ≥25 kg/m2 were assigned to the obesity group. The mean doses of VCM per time (mg/kg) to achieve the target trough concentration of VCM, 15–20 μg/mL, were 19.8 ± 4.3, 16.5 ± 3.7, and 13.7 ± 2.7 mg/kg in the lean, standard, and obesity groups, respectively. The dose per time to achieve the target trough concentration decreased significantly in association with an increase of BMI. The upper limit of the recommended dose (15–20 mg/kg) or higher in lean patients, and the lower dose in obese patients than the recommended dose might be appropriate to achieve the target trough concentration when we calculated the dose per time based on actual body weight.

  • Age-associated theophylline metabolic activity corresponds to the ratio of 1,3-dimethyluric acid to theophylline in mice

    Kuroda Y., Taguchi K., Enoki Y., Matsumoto K., Hori S., Kizu J.

    Biological and Pharmaceutical Bulletin (Biological and Pharmaceutical Bulletin)  42 ( 8 ) 1423 - 1427 2019年

    ISSN  09186158

     概要を見る

    © 2019 The Pharmaceutical Society of Japan. Age is known as one of influencing factor for theophylline (TP)-metabolizing capacity. In a previous our study, the ratio of TP and its major metabolite 1,3-dimethyluric acid (DMU) in serum (DMU/TP) is a useful index to estimate TP-metabolizing capacity, and this value markedly increased by influencing factor, such as the history of smoking. However, it is unknown whether DMU/TP values in serum reflect age-associated changes of TP-metabolizing capacity. In this study, the effect of age on the DMU/TP values in serum were investigated using mice of different age due to the limited blood sampling in human. The concentrations of TP and its metabolites in mouse serum were simultaneously measured using HPLC. As observed in human serum, serum TP concentrations were closely correlated with DMU concentration in mice, which indicates that the DMU/TP ratio is a good indicator of TP metabolic ability in mice. When TP was administered subcutaneously in 2?8-week-old mice, age-associated changes in the DMU/TP ratio in mice were observed. In conclusion, age-associated changes in TP-metabolizing capacity can be estimated by the DMU/TP ratio in serum.

  • Sarcopenia in chronic kidney disease: Factors, mechanisms, and therapeutic interventions

    Watanabe H., Enoki Y., Maruyama T.

    Biological and Pharmaceutical Bulletin (Biological and Pharmaceutical Bulletin)  42 ( 9 ) 1437 - 1445 2019年

    ISSN  09186158

     概要を見る

    © 2019 The Pharmaceutical Society of Japan. Chronic kidney disease (CKD), a chronic catabolic condition, is characterized by muscle wasting and decreased muscle endurance. Many insights into the molecular mechanisms of muscle wasting in CKD have been obtained. A persistent imbalance between protein degradation and synthesis in muscle causes muscle wasting. During muscle wasting, high levels of reactive oxygen species (ROS) and inflammatory cytokines are detected in muscle. These increased ROS and inflammatory cytokine levels induce the expression of myostatin. The myostatin binding to its receptor activin A receptor type IIB stimulates the expression of atrogenes such as atrogin-1 and muscle ring factor 1, members of the muscle-specific ubiquitin ligase family. Impaired mitochondrial function also contributes to reducing muscle endurance. The increased protein-bound uremic toxin, parathyroid hormone, glucocorticoid, and angiotensin II levels that are observed in CKD all have a negative effect on muscle mass and endurance. Among the protein-bound uremic toxins, indoxyl sulfate, an indole-containing compound has the potential to induce muscle atrophy by stimulating ROS-mediated myostatin and atrogenes expression. Indoxyl sulfate also impairs mitochondrial function. Some potential therapeutic approaches based on the muscle wasting mechanisms in CKD are currently in the testing stages.

  • Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS

    Ando G., Taguchi K., Enoki Y., Yokoyama Y., Kizu J., Matsumoto K.

    Biological and Pharmaceutical Bulletin (Biological and Pharmaceutical Bulletin)  42 ( 11 ) 1799 - 1804 2019年

    ISSN  09186158

     概要を見る

    © 2019 The Pharmaceutical Society of Japan. Investigation of the occurrence time of adverse drug reactions helps to prevent the development and aggravation of adverse reactions, but the expression time of ganciclovir-induced adverse events has not been elucidated. In this study, using databases of spontaneous adverse event reports, the Japanese Adverse Drug Event Report database (JADER) and the U.S. Food and Drug Administration (FDA)'s Adverse Event Reporting System (FAERS), the incidence of adverse reactions due to ganciclovir and their expression time were analyzed. As a result of calculation of the reporting odds ratio (ROR) and 95% confidence interval for individual main adverse reactions of ganciclovir (cytopenia, leukopenia, thrombocytopenia, liver damage, and acute renal failure), a signal was detected for all adverse reactions in both databases, except for liver damage in JADER. Furthermore, the Weibull distribution was performed for the analysis of onset time of each ganciclovir-induced adverse event. The results of Weibull parameter α and β values of each adverse event in both JADER and FAERS suggested that most adverse events occurred within 30 d and classified into the early failure type, except that thrombocytopenia and acute renal failure in JADER classified into the random failure type. Based on these findings, it concluded that the paying attention to signs of each ganciclovirinduced adverse event is required from the early phase after ganciclovir administration. However, in FAERS, development after a long-term course also accounted for 11%, suggesting that long-term periodic monitoring of adverse reactions would be also required.

全件表示 >>

研究発表 【 表示 / 非表示

  • ダプトマイシンによりクレアチニンキナーゼが上昇した肥満患者

    榎木裕紀,山本理紗子,佐村優,田口和明,松元一明

    第67回日本化学療法学会総会 (東京) , 2019年05月, ポスター(一般), 日本化学療法学会

  • JADERを用いたClostridium difficile腸炎と偽膜性大腸炎の発現に関する要因解析

    榎木 裕紀

    第65回 日本化学療法学会 東日本支部総会 (東京ドームシティホテル) , 2018年10月, 口頭(一般), 日本化学療法学会

  • 外来静注抗菌薬療法(OPAT)導入に向けたペニシリンGカリウムおよびアンピシリンの各種輸液製剤溶解後の安定性に関する検討

    榎木 裕紀

    第66回日本化学療法学会総会 (岡山) , 2018年05月, ポスター(一般), 日本化学療法学会

  • 慢性腎臓病病態の骨格筋萎縮における尿毒素の関与と新規治療戦略に関する検討

    榎木 裕紀,渡邊 博志,荒毛 里歩,異島 優,松元 一明,小田切 優樹,丸山 徹

    第2回日本老年薬学会学術大会, 2018年05月, 口頭(一般)

  • 高用量シスプラチン療法による腎障害に対するマグネシウム製剤の予防効果の検討

    榎木 裕紀

    第25回医療薬学フォーラム, 2017年07月, ポスター(一般), 日本医療薬学会

競争的資金等の研究課題 【 表示 / 非表示

  • 筋作動因子-尿毒症物質クロストークを標的としたCKD誘発サルコペニアの治療戦略

    2018年04月
    -
    2021年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 榎木 裕紀, 若手研究, 補助金,  代表

 

担当授業科目 【 表示 / 非表示

  • 課題研究(薬効解析学)

    2019年度

  • 演習(薬効解析学)

    2019年度

  • 卒業研究A

    2019年度

  • 実務実習事前学習4

    2019年度

  • 実務実習事前学習1

    2019年度

全件表示 >>